Symbol of the Government of Canada

Common menu bar links

GlaxoSmithKline

Submission — GlaxoSmithKline

Important note: The content of submissions and summaries is the sole responsibility of the person and / or organization having made a submission. The posting of this content does not indicate that the Panel supports or endorses it. Submissions and summaries are posted in the language provided without modification.

Submitter(s): Clow, Dan

Summary: By definition R&D (comprised of basic research, applied research and experimental development) is a subset of the broader term, innovation (which also includes commercialization). Canada has historically focused heavily on investing in early R&D elements but has neglected to adequately support the later elements including commercialization. This provides a likely explanation for why our world-leading investment in R&D (relative to GDP) has not delivered a reciprocal return on innovation and productivity. Instead of investing in innovation – we've been investing in R&D! We need to shift the focus, however, this doesn't necessarily mean shifting government funding out of the research pot since many of the necessary changes don't require a direct financial investment as much as they require that the right policy framework is in place to ensure that incentives to innovation are aligned and impediments are removed.

Full submission: PDF Version